Related Experiment Video
Updated: Sep 20, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Myocardial Iba1, MHC class II, and CD3 are diffusely increased in canine myocarditis: A step toward antemortem
Kristina Vu1, Vanessa Wikel1, Alex Molesan1
1Cornell University, Ithaca, NY.
Insights
Diagnosing canine myocarditis before death is challenging. This study found increased immune markers (MHCII, CD3, Iba1) in canine heart tissue, suggesting a potential for antemortem diagnosis via biopsy.
Area of Science:
- Veterinary Pathology
- Immunohistochemistry
- Canine Cardiology
Background:
- Canine myocarditis is a severe cardiac condition with difficult antemortem diagnosis.
- Current definitive diagnosis requires post-mortem examination.
- Human myocarditis diagnosis utilizes endomyocardial biopsy with histopathology and immunohistology.
Purpose of the Study:
- To evaluate immune response markers in canine myocarditis.
- To establish immunohistologic criteria for canine myocarditis diagnosis.
- To determine if markers MHCII, CD3, and Iba1 are increased in canine myocarditis.
Main Methods:
- Immunohistochemistry was performed on archived canine myocardial tissue from 22 myocarditis cases and 23 controls.
- Analysis focused on major histocompatibility complex class II (MHCII), cluster of differentiation 3 (CD3), and ionized calcium binding adapter molecule 1 (Iba1).
- Fraction of myocardium with marker labeling was quantified, including analysis of samples adjacent to inflammatory foci.
Main Results:
- All three markers (Iba1, MHCII, CD3) were significantly increased in canine myocarditis cases compared to controls.
- Significant increases in Iba1 and CD3 were detected even in samples taken outside of obvious inflammatory areas.
- These findings suggest diffuse immune marker presence in canine myocarditis.
Conclusions:
- Increased levels of MHCII, CD3, and Iba1 are indicative of canine myocarditis.
- Endomyocardial biopsy combined with immunohistochemistry for these markers may enable sensitive antemortem diagnosis.
- Diagnosis may be achievable irrespective of precise tissue sampling location.
Abstract:
Canine myocarditis is a rare but serious health concern, potentially causing heart failure and death. Antemortem diagnosis is hampered by the numerous causes, nonspecific course, and dearth of diagnostic criteria. Currently, definitive diagnosis can only be made after death. The current human diagnostic gold standard is endomyocardial biopsy pairing cardiac histopathology with immunohistology to enhance detection of often-multifocal disease. We evaluated immune response markers in the canine heart to establish similar immunohistologic criteria. We hypothesized that myocardial major histocompatibility complex class II (MHCII), cluster of differentiation 3 (CD3), and ionized calcium binding adapter molecule 1 (Iba1), markers increased in human myocarditis, would be increased in canine myocarditis cases. Archived paraffin-embedded myocardial tissue from 22 histopathologically confirmed cases of adult and juvenile myocarditis and 23 controls was analyzed by immunohistochemistry for MHCII, CD3, and Iba1, and the fraction of myocardium with labeling was determined. All 3 markers were significantly increased compared with controls across the entire section: Iba1, 10.1× (P < .0001, Mann-Whitney U test); MHCII, 3.04× (P = .0019); and CD3, 4.4× (P = .0104). To mimic off-target biopsy, samples from 2 mm2 outside of inflammatory foci were analyzed, and these showed significant increases in Iba1 by 3.2× (P = .0036, Mann-Whitney U test) and CD3 by 1.2× (P = .0026). These data show diffusely increased immune response markers with canine myocarditis, with detection potentially independent of tissue sampling. Thus, endomyocardial biopsy and immunohistochemical detection of MHCII, CD3, and Iba1 may permit sensitive antemortem diagnosis of canine myocarditis.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis III: Medical Management

